| 000 | 01522 a2200409 4500 | ||
|---|---|---|---|
| 005 | 20250518100218.0 | ||
| 264 | 0 | _c20210514 | |
| 008 | 202105s 0 0 eng d | ||
| 022 | _a1468-3083 | ||
| 024 | 7 |
_a10.1111/jdv.16521 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aStrober, B | |
| 245 | 0 | 0 |
_aEfficacy of risankizumab in patients with moderate-to-severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa-1 and UltIMMa-2 studies. _h[electronic resource] |
| 260 |
_bJournal of the European Academy of Dermatology and Venereology : JEADV _cDec 2020 |
||
| 300 |
_a2830-2838 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xtherapeutic use |
| 650 | 0 | 4 | _aBiological Therapy |
| 650 | 0 | 4 | _aDemography |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aPsoriasis _xdrug therapy |
| 650 | 0 | 4 | _aSeverity of Illness Index |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aUstekinumab _xtherapeutic use |
| 700 | 1 | _aMenter, A | |
| 700 | 1 | _aLeonardi, C | |
| 700 | 1 | _aGordon, K | |
| 700 | 1 | _aLambert, J | |
| 700 | 1 | _aPuig, L | |
| 700 | 1 | _aPhotowala, H | |
| 700 | 1 | _aLongcore, M | |
| 700 | 1 | _aZhan, T | |
| 700 | 1 | _aFoley, P | |
| 773 | 0 |
_tJournal of the European Academy of Dermatology and Venereology : JEADV _gvol. 34 _gno. 12 _gp. 2830-2838 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/jdv.16521 _zAvailable from publisher's website |
| 999 |
_c30886495 _d30886495 |
||